Immune-related Adverse Events — CAR T-Cell Therapy
Publication Date: November 1, 2021
Key Points
Key Points
- Immunotherapy has revolutionized the treatment of many different types of cancers.
- Chimeric antigen receptor T-cell (CAR T) therapy, an expanding immunotherapeutic approach, modifies T cells to redirect them to eradicate malignant cells.
- CAR T-cell therapy is regarded as a “living drug” since cells are expected to persist long term with efficacy that may last for decades.
- CAR T-cell therapy is administered with a single infusion and close monitoring.
- CAR T-cell therapy is associated with severe, even fatal, toxicities such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).
- The incidence of CRS has been reported to range from 57%–93%, and ICANS from 20%–70%, based on the agent used.
Key Recommendations
...Key Recommendations...
...re general recommendations that should be fol...
...commended that clinicians manage toxicities...
Management
...Management...
...ommendations In patients with active infe...
...ytokine Release Syndrome Recommendations...
...ecommendations Workup/Eva...
...Hemophagocytic Lymphohistiocytosis (HLH) Recommend...
...penias Recommendations...
...ll Aplasia Recommendations...
...Disseminated Intravascular Coagulation (DIC)...
...ble 7. Infections Workup/...
...8. CAR T-cell Therapies...